An Uncommon Case Report of Hypothyroidism, Type 1 Diabetes Mellitus, and Systemic Lupus Erythematosus with an Immunosuppressive Consequence: A Case Report
Article Sidebar
Main Article Content
Abstract
An autoimmune condition known as Systemic Lupus Erythematosus (SLE) affects several systems and manifests itself in a variety of ways. It is far more common among young women who are fertile.
It has been demonstrated that a mix of environmental and genetic variables may trigger immunological responses, triggering T and B cells, and leading the B cells to overproduce pathogenic autoantibodies and dysregulate cytokines, which ultimately result in harm to many organs and tissues. One feature of SLE is the presence of antibodies against cytoplasmic and nuclear antigens. An autoimmune illness is also type 1 diabetes. β-cell antibodies (Ab) and other antibodies that cause the autoimmune death of the pancreatic β-cells, which make insulin, are part of the multifactorial pathophysiology of type 1 diabetes mellitus (T1DM).
Immunosuppression is the therapy for systemic lupus erythematosus (SLE), and diabetes itself compromises immunity, making infections more opportunistic. We came across an unusual instance of a patient with SLE, T1DM, hypothyroidism on immunosuppression who subsequently acquired pulmonary TB.
Key phrase: Autoimmune diseases such as type 1 diabetes mellitus (T1DM) and Systemic Lupus Erythematosus (SLE).
Article Details
Copyright (c) 2024 Hoda A, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Vaillant AA, Goyal A, Varacallo M. Systemic lupus erythematosus. StatPearls; 2022.
Karrar S, Cunninghame Graham DS. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 2018;70(4):496. Available from: https://doi.org/10.1002/art.40396
Didier K, Charras A, Daïen CI, Toquet S, Robbins A, Antonicelli F, et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol. 2018;9:541. Available from: https://doi.org/10.3389/fimmu.2018.00541
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69-82. Available from: https://doi.org/10.1016/s0140-6736(13)60591-7
Pihoker C, Gilliam LK, Greenbaum CJ, et al. Autoantibodies in diabetes. Diabetes. 2005;54(Suppl 2). Available from: https://doi.org/10.2337/diabetes.54.suppl_2.S52
Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41(1):11-18. Available from: https://doi.org/10.1080/08916930701619169
Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev. 2016;15(7):644-648. Available from: https://doi.org/10.1016/j.autrev.2016.02.017
Kahaly GJ, Frommer L, Schuppan D. Celiac disease and glandular autoimmunity. Nutrients. 2018;10(7):814. Available from: https://doi.org/10.3390/nu10070814
Barker JM. Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab. 2006;91(4):1210-1217. Available from: https://doi.org/10.1210/jc.2005-1679
Kota SK, Kumar KV, Reddy PV, Kota SK, Modi KD. Clinical profile of coexisting conditions in type 1 diabetes mellitus patients. Diabetes Metab Syndr Clin Res Rev. 2012;6(2):70-76. Available from: https://doi.org/10.1016/j.dsx.2012.08.006
Sota S, Umezawa Y, Nakajima A, Insalaco A, Sfriso P, de Vita S, et al. Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease. Front Pharmacol. 2019;10:918. Available from: https://doi.org/10.3389%2Ffphar.2019.00918
Fu SM, Wang P, Kavanaugh A, et al. Anti-dsDNA antibodies are one of the many autoantibodies in systemic lupus erythematosus. F1000Research. 2015;4(F1000 Faculty Rev). Available from: https://doi.org/10.12688/f1000research.6875.1
Flechsig A, Culemann U, Schneider M, Strauss R, Klotsche J, Dähnrich C, et al. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin Exp Rheumatol. 2017;35(4):598-606. Available from: https://pubmed.ncbi.nlm.nih.gov/28281463/
Orozco G, Dota M, Muñoz J, Zhernakova S, Roep BO, González-Gay MA, et al. Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Hum Immunol. 2005;66(12):1235-1241. Available from: https://doi.org/10.1016/j.humimm.2006.02.003
Cortes S, Salazar-Cardozo C, Jara LJ, Isenberg D. Diabetes mellitus complicating systemic lupus erythematosus–analysis of the UCL lupus cohort and review of the literature. Lupus. 2008;17(11):977-980. Available from: https://doi.org/10.1177/0961203308091539
Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005;25:63-68. Available from: https://doi.org/10.1016/j.jaut.2005.10.001
Kordonouri O, Hartmann R, Mohnike K, Grüters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. Diabetes Care. 2002;25(8):1346-1350. Available from: https://doi.org/10.2337/diacare.25.8.1346
Barera G, Wolf J, Bazzigaluppi E, et al. Occurrence of celiac disease after onset of type 1 diabetes: a 6-year prospective longitudinal study. Pediatrics. 2002;109(5):833-838. Available from: https://doi.org/10.1542/peds.109.5.833
Deng Y, Tsao BP. Genetics of human SLE. In: Wallace DJ, Hahn BH, editors. Dubois' Lupus Erythematosus and Related Syndromes. 8th ed. Philadelphia: Elsevier. 2019;54-68.
Odendahl M, Mei H, Radbruch A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000;165(10):5970-5979. Available from: https://doi.org/10.4049/jimmunol.165.10.5970
Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, et al. Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A. 2005;102(51):18425-18430. Available from: https://doi.org/10.1073/pnas.0508621102
Suárez-Fueyo A, Bradley SJ, Tsokos GC. T cells in systemic lupus erythematosus. Curr Opin Immunol. 2016;43:32-38. Available from: https://doi.org/10.1016/j.coi.2016.09.001
Nakayamada S, Tanaka Y. Clinical relevance of T follicular helper cells in systemic lupus erythematosus. Expert Rev Clin Immunol. 2021;17(10):1143-1150. Available from: https://doi.org/10.1080/1744666x.2021.1976146
Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716-730. Available from: https://doi.org/10.1038/nrrheum.2016.186
Giang S, La Cava A. Regulatory T cells in SLE: biology and use in treatment. Curr Rheumatol Rep. 2016;18:1-9. Available from: https://doi.org/10.1007/s11926-016-0616-6
Mellor-Pita S, Citores MJ, Castejon R, Tutor-Ureta P, Yebra-Bango M, Andreu JL, et al. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006;65(4):553-554. Available from: https://doi.org/10.1136/ard.2005.044974
Wong FS, Wen L, Tang M, Ramanathan M, Visintin I, Daugherty J, et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes. 2004;53(10):2581-2587. Available from: https://doi.org/10.2337/diabetes.53.10.2581
Jenks SA, Sanz I. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev. 2009;8(3):209-213. Available from: https://doi.org/10.1016/j.autrev.2008.07.047
Mak AN, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res. 2014;2014:690740. Available from: https://doi.org/10.1155/2014/419029
Clark M, Adams S, Collins J, et al. The role of T cell receptor signaling in the development of type 1 diabetes. Front Immunol. 2021;11:615371. Available from: https://doi.org/10.3389%2Ffimmu.2020.615371
Cook HT, Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006;2(6):330-337. Available from: https://doi.org/10.1038/ncprheum0191
Ajjan RA, Schroeder V. Role of complement in diabetes. Mol Immunol. 2019;114:270-277. Available from: https://doi.org/10.1016/j.molimm.2019.07.031
Chyuan I-T, Tzeng H-T, Chen J-Y. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells. 2019;8(9):963. Available from: https://doi.org/10.3390/cells8090963
Zipris D. Toll-like receptors and type 1 diabetes. In: Davis S, editor. The Islets of Langerhans. 2010; 585-610. Available from: https://doi.org/10.1007/978-90-481-3271-3_25
Fillatreau S, Manfroi B, Dörner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(2):98-108. Available from: https://www.nature.com/articles/s41584-020-00544-4
Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol. 2007;122(1):115-120. Available from: https://doi.org/10.1016/j.clim.2006.10.003
Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C.. Lupus nephritis (Primer). Nat Rev Dis Primers. 2020;6(1):7. Available from: https://doi.org/10.1038/s41572-019-0141-9
Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus. 2005;14(1):13-18. Available from: https://doi.org/10.1191/0961203305lu2053oa
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895. Available from: https://doi.org/10.1056/nejmoa1014460
Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75(1):30-36. Available from: https://doi.org/10.1136/annrheumdis-2014-206456
Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009;18(8):682-689. Available from: https://doi.org/10.1177/0961203308101019
Feng X, Zou Y, Pan W, Wang X, Wu M, Zhang M, et al. Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus. 2014;23(3):327-334. Available from: https://doi.org/10.1177/0961203313513508
Zhou P, Chen J, He J, Zheng T, Yunis J, Mak V, et al. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog. 2021;17(10). Available from: https://doi.org/10.1371/journal.ppat.1009858
González-Echavarri C, Capdevila O, Espinosa G, Suárez S, Marín-Ballvé A, González-León R, et al. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus. 2018;27(14):2253-2261. Available from: https://doi.org/10.1177/0961203318811598